Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Invivyd Invivyd Elects Two New Independent Members to its Board of Directors May 22, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 13, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback May 07, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights May 02, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position April 30, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™ April 15, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces CEO Transition April 12, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million April 04, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights March 28, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial March 22, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 March 22, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 05, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents January 03, 2024 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 December 18, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 09, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights November 02, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Participate in Upcoming Investor Conferences October 31, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 September 11, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Participate in Upcoming Investor Conferences September 06, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Appoints William Duke as Chief Financial Officer September 05, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights August 10, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights August 03, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces Appointment of Sara Cotter to Board Of Directors July 27, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People July 17, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19 June 26, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People June 22, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Participate at the Jefferies Healthcare Conference June 01, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd Reports First Quarter 2023 Financial Results and Business Highlights May 11, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights May 04, 2023 From Invivyd Via GlobeNewswire Tickers IVVD Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.